MEETING PREVIEW: Companies and trends to watch at JP Morgan conference
This article was originally published in Scrip
Executive Summary
Since both seasoned life science investors and relative newcomers to the sector will have time over the holidays to rest prior to the annual JP Morgan Healthcare conference in San Francisco, Big Pharma executives and small biotech CEOs alike may want to spend their time out of the office in late December and early January perfecting answers to investor questions about research, acquisition, product launch and reimbursement strategies for 2013.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.